Market Highlights
According to MRFR analysis, HIV
Drugs Market is expected to register a CAGR of 5% during the
forecast period of 2019 to 2025 and was valued at USD 24 million in
2018.
HIV drugs aim to control
the growth of the human immunodeficiency virus (HIV), improve the patient’s
overall immune system, and reduce/stop the symptoms. The drugs used to treat
HIV infection are antiretrovirals, which help reduce the viral load and fight
the infection.
The growth of the global HIV drug
market is driven by the increasing prevalence of HIV infection, rising
awareness of HIV treatment, and the launch of innovative drugs. However,
stringent regulatory policies for drug approval and product recalls are
expected to curb the growth of the global HIV drug market during the assessment
period. The global HIV drugs market is currently dominated by several market
players. The key players are involved in product launches and strategic
collaborations to strengthen their market positions.
Segmentation
The global HIV drug market has been
segmented based on type and end-user. The market, based on type, has been
divided into nucleoside reverse transcriptase inhibitors (NRTIs),
non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors
(PIs), fusion inhibitors, CCR5 antagonists, integrase inhibitors, post-attachment
inhibitors, and pharmacokinetic enhancers. The drugs
in these different segments differ with respect to their mechanism of treating
the HIV infection. The different approaches for treatment are, inhibiting HIV’s
reverse transcriptase, preventing HIV maturation, and preventing the entry of
the virus into the host cells, among others. The global HIV drugs market has
been segmented based on end-user, into hospitals & clinics, specialty
centers, and others. The hospitals & clinics segment is expected to hold
the largest market share due to an increasing number of hospitals.
Key Players
Some of the key players
in the Global HIV Drugs Market are Boehringer Ingelheim International, GmbH
(Germany), Cipla Inc. (India), Merck & Co., Inc. (US), AbbVie Inc. (US),
Bristol-Myers Squibb Company (US), Teva Pharmaceutical Industries Ltd (Israel),
Gilead Sciences, Inc. (US), F.Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc.
(US), Aurobindo Pharma (India), Celltrion Healthcare Co., Ltd (South Korea),
and ViiV Healthcare (UK).
Regional Analysis
The market has been divided, by
region, into Europe, the Americas, Asia-Pacific, and the Middle East &
Africa. The Americas holds the largest market share. The HIV drugs market in
the Americas has further been branched into North America and Latin America,
with the North American market divided into the US and Canada. Europe is
expected to be the second-largest market owing to factors such as product
launches by key players. The European HIV drugs market has been categorized as
Western Europe and Eastern Europe. The Western European market has further been
classified as Germany, France, the UK, Italy, Spain, and the rest of Western
Europe. The HIV drugs market in Asia-Pacific has been segmented into Japan,
China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the
growing awareness regarding the use of HIV drugs and the increasing incidence
of HIV in the region, the market in Asia-Pacific is expected to be the
fastest-growing. The HIV drugs market in the Middle East & Africa has been
divided into the Middle East and Africa and is expected to hold the least
market share.
No comments:
Post a Comment